Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TKT European Company To Be Led By Ex-P&U Genotropin Team

Executive Summary

Transkarayotic Therapies' newly established European company will be headed by executives who led the EU and Japan launch of Pharmacia & Upjohn's Genotropin.

You may also be interested in...



Transkaryotic Therapies Replagal

BLA submitted June 16 for Fabry disease enzyme replacement injectable agalsidase alfa based on Phase II data. The biologic has orphan drug designation and will receive priority review

EU Orphan Designations Expected By Third Quarter; 24 Applications Received

EMEA's Committee for Orphan Medicinal Products expects to deliver its first orphan drug designations by the third quarter of this year, the committee said.

TKT Hemophilia Gene Therapy Trial Halted Despite No Evidence Of Problems

The suspension of Transkaryotic Therapies' gene therapy trial at Beth Israel Deaconess Medical Center could signal the beginning of a trend of gene therapy trial suspensions as a cautionary measure even if the study shows no sign of problems.

Related Content

UsernamePublicRestriction

Register

PS036394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel